EarningsNon-GAAP EPS of $0.43 missed Consensus largely due to higher-than-expected spending.
Financial Performance1Q24 results were soft, due primarily to an unusually high level of wholesaler destocking of Vivitrol, Aristada, and Lybalvi.
Market CompetitionHarmony Biosciences has entered the space as well, resulting in an even more crowded market.